ZVRA

Zevra Therapeutics INC

+$46.0M

Net Activity

Institutions Holding

147

Popularity Rank

#3592

Avg Weight

0.08%

Total Value

$415.1M

Ownership Trend

147 institutions currently hold ZVRA, with 68 net buyers and 80 net sellers this quarter.

Institutional Moves

Institutional Moves (Q1 2026)

Neutral

Based on recent trading activity

Net Selling Institutions

80

Net Buying Institutions

68

Key Holders

View all 147 holding institutions

Quarterly Activity

Recent Activity

+$241.7M

Total Buy Value

$165.4M

Total Sell Value

New buy14
Trim53
Add54
Sold out27

68

Net Buyers

80

Net Sellers

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

1

Filings (90d)

$156K

Total Est. Value

11K shares

Planned Shares

Last Filed 2026-07-08
FilerFiling DateEst. Value
JOHN BODE2026-07-08$156K

Form 144 is a planned sale notice, not an executed transaction. Form 144 Tracker

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

FAQ

Who are the top institutional investors holding ZEVRA THERAPEUTICS INC (ZVRA)?
Major stakeholders currently include BlackRock, Inc. ($41.5M), Woodline Partners LP ($32.2M), FMR LLC ($29.9M). Based on the latest 13F filings, there are a total of 147 tracked investment funds and institutions maintaining positions in ZVRA.
What is the overall institutional sentiment toward ZVRA recently?
Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $46.0M, driven by 68 managers accumulating shares while 80 reduced their exposure.
Which institutions have been selling or reducing their ZVRA positions?
In the latest period, 53 funds trimmed their holdings, and 27 managers completely exited their positions. The aggregate reported sell value was $165.4M.
Are there any notable investors adding ZVRA to their portfolios?
Yes, buying activity remains notable. 14 institutions opened new positions in {ticker}, and 54 existing holders added to their shares. The total reported buy value for the quarter amounted to $241.7M.

Related Stocks